JunB is a gatekeeper for B-lymphoid leukemia

Oncogene

Volumn 26, Issue 33, 2007, Pages 4863-4871

  Ott, R G ^a   Simma, O ^a   Kollmann, K ^a   Weisz, E ^a   Zebedin, E M ^a   Schorpp Kistner, M ^b   Heller, G ^a   Zochbauer S ^a   Wagner, E F ^c   Freissmuth, M ^a   Sexl, V ^a,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Cancer Center   (Austria)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^d Department of Pharmacology ^*  (Austria)

Author keywords

AP 1; bcr abl; JunB; Leukemia

Indexed keywords

BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE 6; PROTEIN P16; PROTEIN P16INK4A; PROTEIN P185; RAG2 PROTEIN; TRANSCRIPTION FACTOR JUNB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DNA METHYLATION; FETUS; INCIDENCE; LEUKEMOGENESIS; LYMPHATIC LEUKEMIA; MALIGNANT TRANSFORMATION; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA-BINDING PROTEINS; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, LYMPHOCYTIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-JUN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSFECTION;

MUS; PYRONIA TITHONUS;

EID: 34447645806     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210285     Document Type: Article

References (35)

1. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. (1993). Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7: 812-821.
2. CorcoranMM,Mould SJ, Orchard JA, Ibbotson RE, Chapman RM, Boright AP et al. (1999). Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene 18: 6271-6277.
3. Deininger M, Buchdunger E, Druker BJ. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653.
4. Diehl JA, Sherr CJ. (1997). A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol 17: 7362-7374.
5. Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M et al. (2003). Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112: 181-192.
6. Ezhevsky SA, Nagahara H, Vocero-Akbani AM, Gius DR, Wei MC, Dowdy SF. (1997). Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci USA 94: 10699-10704.
7. Grawunder U, Melchers F, Rolink A. (1993). Interferon-gamma arrests proliferation and causes apoptosis in stromal cell/interleukin-7-dependent normal murine pre-B cell lines and clones in vitro, but does not induce differentiation to surface immunoglobulin-positive B cells. Eur J Immunol 23: 544-551.
8. Hai T, Curran T. (1991). Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci USA 88: 3720-3724.
9. Halazonetis TD, Georgopoulos K, Greenberg ME, Leder P. (1988). c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell 55: 917-924.
10. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
11. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826.
12. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ et al. (1998). Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95: 7556-7561.
13. Kenner L, Hoebertz A, Beil T, Keon N, Karreth F, Eferl R et al. (2004). Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol 164: 613-623.
14. Lee W, Mitchell P, Tjian R. (1987). Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 49: 741-752.
15. Li LC, Dahiya R. (2002). MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431.
16. Mao X, Lillington D, Child F, Russell-Jones R, Young B, Whittaker S. (2002). Comparative genomic hybridization analysis of primary cutaneous B-cell lymphomas: identification of common genomic alterations in disease pathogenesis. Genes Chromosomes Cancer 35: 144-155.
17. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ. (2003). Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 101: 1513-1519.
18. Marique T, Werenne J. (2001). Control of 92 kDa collagenase secretion in mammalian cells by modulation of AP-1 activity: an experimentally based theoretical study. J Theor Biol 209: 3-8.
19. Markevich NI, Hoek JB, Kholodenko BN. (2004). Control of 92 kDa collagenase secretion in mammalian cells by modulation of AP-1 activity: an experimentally based theoretical study. J Cell Biol 164: 353-359.
20. Mechta-Grigoriou F, Gerald D, Yaniv M. (2001). The mammalian Jun proteins: redundancy and specificity. Oncogene 20: 2378-2389.
21. Passegue E, Jochum W, Schorpp-Kistner M, Mohle-Steinlein U, Wagner EF. (2001). Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 104: 21-32.
22. Passegue E, Wagner EF, Weissman IL. (2004). JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119: 431-443.
23. Rassidakis GZ, Thomaides A, Atwell C, Ford R, Jones D, Claret FX et al. (2005). JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol 18: 1365-1370.
24. Schorpp-Kistner M, Wang ZQ, Angel P, Wagner EF. (1999). JunB is essential for mammalian placentation. EMBO J 18: 934-948.
25. Sexl V, Diehl JA, Sherr CJ, Ashmun R, Beach D, Roussel MF. (1999). A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. Oncogene 18: 573-582.
26. Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, Bunting KD et al. (2000). Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood 96: 2277-2283.
27. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al. (2001). IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
28. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. (1997). Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 11: 1464-1478.
29. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M et al. (1992). RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68: 855-867.
30. Szabowski A, Maas-Szabowski N, Andrecht S, Kolbus A, Schorpp-Kistner M, Fusenig NE et al. (2000). c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell 103: 745-755.
31. Szremska AP, Kenner L, Weisz E, Ott RG, Passegue E, Artwohl M et al. (2003). JunB inhibits proliferation and transformation in B-lymphoid cells. Blood 102: 4159-4165.
32. Vogelstein B, Kinzler KW. (2004). Cancer genes and the pathways they control. Nat Med 10: 789-799.
33. Wolff L, Garin MT, Koller R, Bies J, Liao W, Malumbres M et al. (2003). Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-deficient mice. Oncogene 22: 9265-9274.
34. Wu JX, Carpenter PM, Gresens C, Keh R, Niman H, Morris JW et al. (1990). The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 5: 989-1000.
35. Yang MY, Liu TC, Chang JG, Lin PM, Lin SF. (2003). JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood 101: 3205-3211.